Skip to main content

Table 2 Logistic regression analysis for UTRN expression and clinical characteristics in TCGA patients

From: UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways

Characteristic N OR P value
T (T1T2 vs. T3T4) 399 0.57 (0.36–0.87) 0.01
N (N0 vs. N1N2) 344 1.05 (0.68–1.64) 0.82
M (M0 vs. M1) 423 1.11 (0.46–2.72) 0.81
Clark level (I/II/III vs. IV/V) 309 0.54 (0.33–0.88) 0.01
Ulceration (no vs. yes) 304 0.59 (0.37–0.92) 0.02
Site (extremities vs. trunk) 355 1.11 (0.73–1.68) 0.64
Age (< 60 vs. ≥ 60) 447 0.78 (0.54–1.14) 0.20
Gender (female vs. male) 447 1.2 (0.82–1.76) 0.35
Height (< 170 vs. ≥ 170) 234 1.52 (0.90–2.55) 0.12
Cancer status (tumor free vs. with tumor) 423 1.34 (0.92–1.97) 0.13
Race (Asian vs. White) 438 1.77 (0.53–6.86) 0.37
Radiation therapy (no vs. yes) 405 1.19 (0.72–1.98) 0.50
Weight (< 80 vs. ≥ 80) 240 178 (1.07–2.98) 0.03
  1. The univariate analysis investigated that UTRN expression was significantly correlated with T stage, Clark level and ulceration in melanoma patients. Categorical dependent variable, greater or less than the median expression level